Deal Making in Oncology
September 2006
Deal Making in Oncology
The Fifth Edition of PharmaVentures Business Review
Watch the whole program
Deal Making in Oncology
The focus of the September edition of PharmaVentures Business Reviews is deal making in oncology. We discuss the trends in oncology deal making since 2000 with an emphasis on licensing agreements and the leading deal-makers in this sector. We review the key issues in oncology deal-making that face both small biotech companies and big pharma with this month's industry experts. As always, we have our round-up of the most important and interesting deals from the previous month's industry activities.
To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.
- AstraZeneca's and POZEN's US$375 M collaborative R&D agreement to develop a new PPI/NSAID combination therapy to treat arthritis-associated pain.
- Becton, Dickinson and Company's proposed acquisition of TriPath Imaging to expand its cancer diagnostic business sector.
- GlaxoSmithKline's US$1.5635 B drug discovery alliance with ChemoCentryx to develop a portfolio of products to treat inflammatory disorders
- MedImmune's and Infinity Pharmaceuticals' US$500 M collaborative R&D agreement to develop novel cancer products that target HSP90 and the Hedgehog pathway.
Watch this segment
The Month in Review
Provides an overview and insight for the following deals and transactions:
To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.
- AstraZeneca's and POZEN's US$375 M collaborative R&D agreement to develop a new PPI/NSAID combination therapy to treat arthritis-associated pain.
- Becton, Dickinson and Company's proposed acquisition of TriPath Imaging to expand its cancer diagnostic business sector.
- GlaxoSmithKline's US$1.5635 B drug discovery alliance with ChemoCentryx to develop a portfolio of products to treat inflammatory disorders
- MedImmune's and Infinity Pharmaceuticals' US$500 M collaborative R&D agreement to develop novel cancer products that target HSP90 and the Hedgehog pathway.
Watch this segment
The Business Report
This month's business report looks at trends in deal making within the oncology sector. Using data from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, we take a look at changes in the number and type of oncology deals that have been signed since 2000. We then focus on licensing deals and investigate the trends in the types of company, product and phase of development and identify which are the most prolific deal making companies in this sector. We also discuss the relative attrition rates for products in this field of therapeutic medicine.
Watch this segment
Meet the Experts
Fintan Walton leads this month's expert panel discussion on the topic of oncology deal making. The panel explores the issues facing big pharma and small biotech and the alliance strategies they employ to ensure that new products and innovation are delivered to serve areas of unmet clinical need in cancer therapeutics.
On this month's panel:
Dr Satu Vainikka,
CEO Cronos Therapeutics
Dr Ray Hill
Executive Director, Licensing and External Research, Europe
Merck & Co.
Dr Tibor Papp,
Head of Consultancy
PharmaVentures
